Beamtree (ASX: BMT) lacks a focus on statutory profitability but a private acquirer that could mandate cost discipline and turn it profitable.

Pathology workflow software stock Beamtree (ASX: BMT) saw its share price fall from almost 20x revenue per share to around 3x.